Surgical intervention in the form of sigmoid colectomy or proctocolectomy and ileostomy may be required only when all conservative measures of evacuation fail. Attempts at removal can have severe and even lethal effects, such as the rupture of the colon wall by catheter or an acute angle of the fecaloma (stercoral perforation), followed by sepsis. It may also lead to stercoral perforation, a condition characterized by bowel perforation due to pressure necrosis from a fecal mass or fecaloma. See also
Aerosol impaction
Colon
Dental impaction
Impaction (animals)

References
Further reading
Wrenn K (September 1989). "Fecal impaction". The New England Journal of Medicine. 321 (10): 658–62. doi:10.1056/NEJM198909073211007. PMID 2671728. Dugdale, David C. (January 31, 2011). "Fecal impaction". A.D.A.M., Inc.
Gattuso JM, Kamm MA, Halligan SM, Bartram CI (April 1996). "The anal sphincter in idiopathic megarectum: effects of manual disimpaction under general anesthetic". Diseases of the Colon and Rectum. 39 (4): 435–9. doi:10.1007/bf02054060. PMID 8878505. S2CID 40482887. == External links ==
Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit.In December 2011, Novartis halted a trial of the drug after discovering increased nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney problems.As a result, in 2012:

A new contraindication was added to the product label concerning the use of aliskiren with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes because of the risk of kidney impairment, low blood pressure, and high levels of potassium in the blood. A warning to avoid use of aliskiren with ARBs or ACEIs was also added for patients with moderate to severe kidney impairment (i.e., where glomerular filtration rate is less than 60 ml/min). Novartis decided to stop marketing Valturna (aliskiren/valsartan).Aliskiren was co-developed by the Swiss pharmaceutical companies Novartis and Speedel. Medical uses
While used for high blood pressure, other better-studied medications are typically recommended. Prescrire has stated that aliskiren is potentially more harmful than beneficial and thus list it as a drug to avoid (as of 2014).